270 Vision Limited

Founded in 2011, 270 Vision are developers of simple-to-use, highly-accurate body analysis technology for use in injury prevention and rehabilitation in the medical, employee welfare and elite sports sectors. With 9 UK patents granted in the UK, 4 in the US, and 1 in the EU with a further one pending, multi-award winning 270 Vision are internationally renowned as the market leaders in motion sensor design and development. Recognised for their work in the industry, the Founders are Senior Associate Members of the Royal Society of Medicine. In 2018, 270 Vision won the prestigious Outstanding Achievement Award at the national Medilink UK Healthcare Business Awards. Having developed their advanced, medical-grade BPMpro sensor technology and undertaken commercial pilots with elite sporting organisations and orthopaedic surgeons, 270 Vision developed BPMpathway – the proven dimension in remote patient assessment in the critical weeks after orthopaedic surgery - named Best Digital Health Platform in the 2018 Juniper Research Future Digital Awards. BPMpathway has the potential to deliver massive benefits for NHS trusts, clinicians and patients by uniquely offering cost-effective, reliable and patented award-winning technology in support of remote patient assessment undertaken by clinicians. With BPMpathway, patients can be discharged as early as the day of their surgery to continue their rehabilitation at home under self-direction, with clinicians remotely assessing their recovery. B. Braun AG, one of the world’s leading manufacturers of medical devices invested into 270 Vision as part of their strategy of securing access to key future technology in e-health. Its third generation sensor technology, WPMpro, is a simple, cost-effective system at the forefront of the next generation of wearable sensor technology with multiple, smart, autonomous sensors detecting excessive joint ROM to help prevent musculoskeletal disorders in the workplace.